

Publications of the Week
Upregulation of Mitochondrial ATPase Inhibitory Factor 1 (ATPIF1) Mediates Increased Glycolysis in Mouse Hearts

 First Author: Bo Zhou | Senior Author: Rong Tian (pictured, middle row, center)
 The Journal of Clinical Investigation | UW


In hypertrophied and failing hearts, fuel metabolism is reprogrammed to increase glucose metabolism, especially glycolysis. Mechanisms responsible for the switch are poorly understood. The authors found that ATPIF1, a protein known to inhibit ATP hydrolysis by the reverse function of ATP synthase during ischemia, was significantly upregulated in pathological cardiac hypertrophy induced by pressure overload, myocardial infarction, or α -adrenergic stimulation. [Profile](#) | [Abstract](#)


Synthetic Lethal Kinases in Ras/p53 Mutant Squamous Cell Carcinoma

 First Author: Russell Moser | Senior Author: Christopher Kemp (pictured)
 Oncogene | Fred Hutch, Institute for Systems Biology, and SEngine Precision Medicine


The oncogene Ras and the tumor suppressor gene p53 are frequently co-mutated in human cancer. To discover novel druggable targets for cancers carrying co-mutations in Ras and p53, the authors performed arrayed, kinase focused small interfering RNA and oncology drug phenotypic screening utilizing a set of syngeneic Ras mutant squamous cell carcinoma cell lines that also carried co-mutations in selected p53 pathway genes. [Profile](#) | [Abstract](#)

[View All Publications](#)
Awards
Genome and Global Health Scientists on TIME100

UW Medicine



Genome scientist Dr. Evan Eichler (pictured, left) and global health researcher Dr. Tullio de Oliveira (right) have been named to 2022 TIME100, the magazine's annual list of the hundred most influential people over the past year. Both UW Medicine-affiliated 2022 TIME 100 honorees work in genomics: one on the human genome, the other on emerging pathogens. [Read More](#)

[View All Awards](#)
Local News
Test of a New 'Germline-Targeting' HIV Vaccine Prepares to Launch

Fred Hutch



Since 2013, Dr. Leo Stamatatos (pictured) has been developing a different kind of HIV vaccine intended to train a person's immune system to mount a powerful antibody response against the virus that causes AIDS. Now, after nine years of refinement at Fred Hutch, it is nearly ready for its first phase of testing in human volunteers. Aside from assuring the safety of the vaccine, the trial will analyze how B cells respond to the vaccine's ingredients. [Read More](#)

Longtime UW Science Leader Nora Disis on Gender Inequity, Translational Research, and More

GeekWire



Dr. Mary "Nora" Disis (pictured) has seen a lot of change in her 30 years at UW. And she's also helped create it, as the Director of the Institute of Translational Health Sciences, which fosters the flow of science into the clinic. "Our purpose here at the UW is to try to turn the entire Pacific Northwest into a translational research engine," said Dr. Disis, a Professor of Medical Oncology who has led the program since its start in 2007. [Read More](#)

Umoja Biopharma and Lupagen Announce New Collaboration to Improve Patient Experience and Access to Next-Generation *In Vivo* Therapeutics for Cancer

Umoja Biopharma



Umoja Biopharma and Lupagen, a gene therapy company developing gene delivery technologies for CAR T, gene editing and immunotherapy products, announced they have entered into a collaboration to evaluate extracorporeal *in vivo* delivery as a potential additional route of administration for Umoja's VivoVec particles using Lupagen's Side CAR T™ technology. [Read More](#)

Seagen Announces Positive Topline Results of Pivotal Phase II Clinical Trial of TUKYSA® (Tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer

Seagen



Seagen announced positive topline results from the pivotal Phase II MOUNTAINEER clinical trial investigating TUKYSA® in combination with trastuzumab in patients with previously treated HER2-positive metastatic colorectal cancer. Data from this trial will form the basis of a planned supplemental New Drug Application to the US Food and Drug Administration (FDA) under the FDA's Accelerated Approval Program. [Read More](#)

Indigenous Health Equity Focus of Pathways Symposium

Fred Hutch



Craig Dee, a community health educator for Indigenous populations, welcomed attendees to the Fred Hutch Pathways to Equity Symposium, which this year focused on Indigenous health inequities. Keynote speaker Dr. Donald Warne (pictured) of the University of North Dakota spoke about the need for greater Indigenous representation in cancer research as well as academic leadership. [Read More](#)

Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davocetcept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences



Alpine Immune Sciences, a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, announced that the US Food and Drug Administration (FDA) has removed the partial clinical hold placed on its NEON-2 trial evaluating davocetcept, a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in adults with advanced malignancies. [Read More](#)

[View All Articles](#) | [Submit an Article](#)
Upcoming Events in Seattle

June 1

12:00 PM

LSWI Grant Writing Workshop: Demystifying SBIR/STTR Funding Part 1
 Online

June 7

4:00 PM

Research Roundtable with Chris Lausted and Dr. Danielle Vermaak
 Online

June 8

10:30 AM

Distinguished Seminar: Paul Cisek
 Online

June 13 - 14

8:00 AM

Mutational Scanning Symposium 2022
 Online

June 16 - 17

8:00 AM

2022 Annual Lung Cancer SPORE Workshop
 Online

[View All Events](#) | [Submit an Event](#)
Science Jobs in Seattle
Biostatistician

Sage Bionetworks

Clinical Research Coordinator II

Seattle Children's

Scientist, Neural Data Analysis

Allen Institute

Internship, Clinical Development

Systimmune

Associate Director, Pharmacokinetics Laboratory

Fred Hutch

[View 108 Other Science Jobs](#) | [Submit a Job](#)

Win a Bluetooth Speaker!
 Subscribe to our newsletter for a chance to win.

 Submit your articles and events by reaching out to us at info@scienceinseattle.com.

BROUGHT TO YOU BY


STEMCELL Technologies

Products | Services

STEMCELL Science News

Free Weekly Updates on Your Field

The Stem Cell Podcast

Interviews and Updates on Stem Cell Science